Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bayarmagnai Weinstein, Bogdan Muresan, Sara Solano, Antonio Vaz de Macedo, YoonJung Lee, Yu-Chen Su, Yeseul Ahn, Gabriela Henriquez, Christina Carmago, Gwang-Jin Kim, David O. Carpenter
Formato: article
Lenguaje:EN
Publicado: University of Minnesota Libraries Publishing 2021
Materias:
Chimeric Antigen Receptor (CAR), Diffuse Large B Cell Lymphoma (DLBCL), Lymphoma, Comparative Effectiveness Study, Matching Adjusted Indirect Comparison, Systematic Literature Review, Axicabtagene ciloleucel (Yescarta)
Pharmacy and materia medica
RS1-441
Acceso en línea:https://doaj.org/article/845e08d651ef47c5be4a6d7ead52914f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares